Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00707512 · ClinicalTrials.gov registry record
CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
A clinical trial, sponsored by Biogen.
- Terminated
- Registry status
- 87
- Enrollment target
NCT00707512: Clinical Trial study, sponsored by Biogen.
NCT00707512 is a clinical trial that was terminated before completion, run by Biogen. The registered enrollment target is 87 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00707512 was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- 87 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the incidence and pattern of serious and/or clinically significant infections, malignancies, and other serious adverse event (SAE) in participants with Crohn's Disease (CD) treated with natalizumab. The secondary objective of this study in this study population is to evaluate disease severity over time in participants with CD treated with natalizumab based on changes in the Harvey-Bradshaw Index (HBI).
Interventions
- DRUG natalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2008-06-30 |
| Est. Completion | 2015-05-28 |
Why NCT00707512 stopped before completion
NCT00707512 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 87 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which natalizumab is the first listed.
NCT00707512 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00707512 about?
NCT00707512 is a clinical study titled "CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring". The primary objective of the study is to determine the incidence and pattern of serious and/or clinically significant infections, malignancies, and other serious adverse event (SAE) in participants with Crohn's Disease (CD) treated with natalizumab. The secondary objective of this study in this stud...
What is the current status of trial NCT00707512?
This trial is currently terminated. The enrollment target is 87 participants. The study started on 2008-06-30. Estimated completion is 2015-05-28.
What interventions are being tested in trial NCT00707512?
The interventions under investigation include: natalizumab (DRUG).
Who is sponsoring clinical trial NCT00707512?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI